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High-dose methotrexate-based chemotherapy has extended survival in patients 
with primary central nervous system lymphoma (PCNSL). However, although sal-
vage treatment is necessary in recurrent and refractory PCNSL, this has not been 
standardized. We herein describe the efficacy of a combination of rituximab and 
temozolomide (TMZ) in two consecutive patients with recurrent and refractory 
PCNSL. Based on the immunohistochemical study, case 1 had a non-germinal 
center B-cell-like (non-GCB) subtype, was positive for bcl-2 and negative for O6-
methylguanine-DNA methyltransferase (MGMT). Case 2 was GCB subtype, bcl-
2-, and MGMT+. Because of the positive expression of MGMT, interferon-beta 
was additionally given in case 2. Complete responses and partial responses were 
obtained after the third and fourth cycles of combination therapy, respectively. 
This was maintained for 12 months, with acceptable toxicity. The combination of 
rituximab and TMZ was effective in tumors with different immunohistochemical 
profiles. This combination therapy warrants further study in a larger population.
Key Words:    Primary central nervous system lymphoma, rituximab, temozolo-
mide, interferon-beta, salvage treatment
INTRODUCTION
The use of high-dose methotrexate (MTX)-based systemic chemotherapy has im-
proved the survival of patients with primary central nervous system lymphoma 
(PCNSL).1 However, salvage treatment is necessary in patients with recurrent and 
refractory disease. The optimal salvage therapy is not yet known.
Temozolomide (TMZ) is an alkylating agent, and has emerged as a treatment 
option for PCNSL because of its good penetration of the blood-brain barrier (BBB) 
and mild toxicity profile. Rituximab is a chimeric monoclonal antibody that targets 
the B cell specific CD-20 antigen. Synergism has been observed for the combina-
tion of rituximab with cyclophosphamide, doxorubicin, vincristine, and predni-
sone (CHOP) in patients with systemic, CD20-positive diffuse large B-cell lym-Mineko Murakami, et al.
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every 14 days, 3 cycles) followed by radiotherapy (30 Gy 
whole brain plus a local boost of 10 Gy for the residual tu-
mor), he had been in complete remission (CR) for a total of 
20 months. Eastern Cooperative Oncology Group perfor-
mance status (PS) was listed as 2 due to motor aphasia and 
right hemiparesis during in CR.
On admission, magnetic resonance image (MRI) revealed 
a small recurrent tumor in the right frontal lobe (Fig. 1A). 
PS had deteriorated to 3. The combination of rituximab and 
TMZ was started (TMZ 150 mg/m2 on day 1 to 5 and intra-
venous rituximab 375 mg/m2 on day 6, every 28 days). After 
3 cycles of this combination chemotherapy, MRI revealed 
CR of the tumor (Fig. 1B). Thereafter, he received a total of 8 
cycles of maintenance TMZ monotherapy; 150 mg/m2 for 
the first 5 days, escalated to 200 mg/m2 in following cycles, 
every 28 days. No corticosteroids were given during the 
combination chemotherapy and TMZ monotherapy. He ex-
perienced no toxicity during the combination chemothera-
py, although grade 3 leukopenia was observed during the 
TMZ monotherapy. The last patient follow-up was in No-
vember 2008. Although PS had deteriorated to 4 due to mo-
tor aphasia, right hemiparesis, incontinence, and cognitive 
dysfunction, he has remained in CR for 12 months.
Case 2
A 66-year-old man was admitted to our hospital in March 
2007 with right hemiparesis. MRI revealed a large tumor in 
the left basal ganglia and left temporal lobe (Fig. 2A). Partial 
resection of the tumor was performed and the diagnosis was 
DLBCL, having a GCB subtype (CD10+/bcl-6+/MUM1+); 
immunopositive for CD20; negative for bcl-2 and positive 
for MGMT. Three cycles of intravenous high-dose MTX 
resulted in disease progression on MRI. He then received ra-
diotherapy, achieving a partial response (Fig. 2B). PS was 
phoma (DLBCL).2 Such synergism allows for a combination 
of rituximab and TMZ in the treatment of PCNSL.
We describe our experience using a combination of ritux-






A 53-year-old man was admitted to our hospital in August 
2007 with gait deterioration and urinary incontinence de-
spite absence of meningeal dissemination. He was previous-
ly diagnosed as having a PCNSL in the left basal ganglia 
and the left temporal lobe in 2005, and the pathological di-
agnosis was confirmed as DLBCL, having a non-germinal 
center B-cell-like (non-GCB) subtype (CD10-/bcl-6-/
MUM1+); immunopositive for CD20; positive for bcl-2 and 
negative for O6-methylguanine-DNA methyltransferase 
(MGMT), by immunohistochemical studies. After treatment 
with intravenous infusion of high-dose MTX (3.5 mg/m2, 
A
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Fig. 1. Gd-enhanced T1-weighted MRI of case 1: (A) MRI on admission in 
August 2007, showing the recurrent tumor in the right caudate head. (B) 
MRI after 3 cycles of combination therapy. The recurrent tumor in the right 
caudate head has disappeared. MRI, magnetic resonance image.
Fig. 2. Gd-enhanced T1-weighted MRI of case 2: (A) Initial MRI in March 2007 shows a large tumor in the left basal ganglia and temporal lobe. (B) MRI after 
treatment with high-dose MTX chemotherapy and radiotherapy shows partial response of the tumor. (C) MRI after 4 cycles of combination therapy. The tu-
mor has reduced in size. (D) MRI in November 2008. Although the tumor in the left basal ganglia shows further shrinkage, multiple new lesions are observed.  
MRI, magnetic resonance image; MTX, methotrexate.Rituximab and TMZ Therapy for Recurrent PCNSL
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ing that the addition of rituximab overcomes the adverse 
prognostic influence of negative bcl-6 expression and posi-
tive expression of bcl-2 on survival in systemic DLB-
CL.10-12 Most PCNSL tumors were classified as non-GCB 
subtype, and the prognostic impact of bcl-6 and bcl-2 status 
remains controversial.13-15 
Two retrospective series of a combination of rituximab 
and TMZ as salvage chemotherapy against PCNSL have 
been reported.16,17 One study with 15 patients reported a 53% 
objective response rate and a median overall survival of 14 
months with a 7 days on/7 days off schedule of TMZ com-
bined with rituximab in a 28-day cycle, followed by main-
tenance treatment with TMZ.16 In the other study, 7 patients 
received 5 days of TMZ with rituximab in a 28-day cycle, 
followed by maintenance monotherapy of TMZ.17 That study 
reported a 100% objective response rate and a median over-
all survival of 8 months. The prognostic influence of tumor 
MGMT status, as well as that of subtype bcl-2 and bcl-6 
expression, in patients receiving rituximab plus TMZ re-
mains to be examined.
In the present two consecutive cases, although both had a 
poor PS and the immunohistochemical profiles differed; 
rituximab/TMZ/±interferon-beta combination treatment 
was effective. Despite limited data, the observed responses 
are encouraging and warrant further investigation in a larg-
er population.
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